Abstract
Salvia miltiorrhiza Bunge, also known as Danshen in Chinese, has been widely used to treat cardiovascular diseases (CVD) in China and other Asia countries. Here, we summarize literatures of the historical traditional Chinese medicine (TCM) interpretation of the action of Salvia miltiorrhiza, its use in current clinical trials, its main phytochemical constituents and its pharmacological findings by consulting Pubmed, China Knowledge Resource Integrated, China Science and Technology Journal, and the Web of Science Databases. Since 2000, 39 clinical trials have been identified that used S. miltiorrhiza in TCM prescriptions alone or with other herbs for the treatment of patients with CVD. More than 200 individual compounds have been isolated and characterized from S. miltiorrhiza, which exhibited various pharmacological activities targeting different pathways for the treatment of CVD in various animal and cell models. The isolated compounds may provide new perspectives in alternative treatment regimes and reveal novel chemical scaffolds for the development of anti-CVD drugs. Meanwhile, there are also some rising concerns of the potential side effects and drug-drug interactions of this plant. The insights gained from this study will help us to better understanding of the actions of this herb for management of cardiovascular disorders. As an herb of red root, S. miltiorrhiza will act as a potential red light to prevent the development of CVD.
Keywords: Salvia miltiorrhiza, traditional chinese medicine (TCM), clinical trials, phytochemistry, pharmacology, cardiovascular disease.
Current Pharmaceutical Design
Title:Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Volume: 23 Issue: 7
Author(s): Lili Wang, Rufeng Ma, Chenyue Liu, Haixia Liu, Ruyuan Zhu, Shuzhen Guo, Minke Tang, Yu Li, Jianzhao Niu, Min Fu, Sihua Gao*Dongwei Zhang*
Affiliation:
- Diabetes Research Center, Beijing University of Chinese Medicine, Beijing, 100029,China
- Diabetes Research Center, Beijing University of Chinese Medicine, Beijing, 100029,China
Keywords: Salvia miltiorrhiza, traditional chinese medicine (TCM), clinical trials, phytochemistry, pharmacology, cardiovascular disease.
Abstract: Salvia miltiorrhiza Bunge, also known as Danshen in Chinese, has been widely used to treat cardiovascular diseases (CVD) in China and other Asia countries. Here, we summarize literatures of the historical traditional Chinese medicine (TCM) interpretation of the action of Salvia miltiorrhiza, its use in current clinical trials, its main phytochemical constituents and its pharmacological findings by consulting Pubmed, China Knowledge Resource Integrated, China Science and Technology Journal, and the Web of Science Databases. Since 2000, 39 clinical trials have been identified that used S. miltiorrhiza in TCM prescriptions alone or with other herbs for the treatment of patients with CVD. More than 200 individual compounds have been isolated and characterized from S. miltiorrhiza, which exhibited various pharmacological activities targeting different pathways for the treatment of CVD in various animal and cell models. The isolated compounds may provide new perspectives in alternative treatment regimes and reveal novel chemical scaffolds for the development of anti-CVD drugs. Meanwhile, there are also some rising concerns of the potential side effects and drug-drug interactions of this plant. The insights gained from this study will help us to better understanding of the actions of this herb for management of cardiovascular disorders. As an herb of red root, S. miltiorrhiza will act as a potential red light to prevent the development of CVD.
Export Options
About this article
Cite this article as:
Wang Lili, Ma Rufeng, Liu Chenyue, Liu Haixia, Zhu Ruyuan, Guo Shuzhen, Tang Minke, Li Yu, Niu Jianzhao, Fu Min, Gao Sihua*, Zhang Dongwei*, Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases, Current Pharmaceutical Design 2017; 23 (7) . https://dx.doi.org/10.2174/1381612822666161010105242
DOI https://dx.doi.org/10.2174/1381612822666161010105242 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of the Chemokines in Myocardial Ischemia and Reperfusion
Current Vascular Pharmacology Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Autophagy: A Major Target of Cadmium Nephrotoxicity
Current Chemical Biology CD36 and Intestinal Fatty Acid Absorption
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Regulation of Oxidative Stress and Cardioprotection in Diabetes Mellitus
Current Cardiology Reviews Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Immunologic Considerations in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Recent Patents and Advances in the Next-Generation Sequencing Technologies
Recent Patents on Biomedical Engineering (Discontinued) Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery
Current Pharmaceutical Design MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Surgical Management of Heart Failure
Current Cardiology Reviews Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Phosphorylated and O-GlcNAc Modified IRS-1 (Ser1101) and -2 (Ser1149) Contribute to Human Diabetes Type II
Protein & Peptide Letters Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry